KR102228571B9 - 정신질환 또는 중추신경계 질환 치료용 약물전달 제형 - Google Patents

정신질환 또는 중추신경계 질환 치료용 약물전달 제형

Info

Publication number
KR102228571B9
KR102228571B9 KR1020170018235A KR20170018235A KR102228571B9 KR 102228571 B9 KR102228571 B9 KR 102228571B9 KR 1020170018235 A KR1020170018235 A KR 1020170018235A KR 20170018235 A KR20170018235 A KR 20170018235A KR 102228571 B9 KR102228571 B9 KR 102228571B9
Authority
KR
South Korea
Prior art keywords
psychosis
treatment
drug delivery
central nervous
delivery system
Prior art date
Application number
KR1020170018235A
Other languages
English (en)
Other versions
KR102228571B1 (ko
KR20180092497A (ko
Inventor
김문석
허지연
Original Assignee
주식회사 메디폴리머
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 메디폴리머 filed Critical 주식회사 메디폴리머
Priority to KR1020170018235A priority Critical patent/KR102228571B1/ko
Priority to JP2019543230A priority patent/JP6893369B2/ja
Priority to EP18751180.3A priority patent/EP3581175B1/en
Priority to PCT/KR2018/001719 priority patent/WO2018147660A1/ko
Priority to US16/484,870 priority patent/US11337929B2/en
Publication of KR20180092497A publication Critical patent/KR20180092497A/ko
Application granted granted Critical
Publication of KR102228571B1 publication Critical patent/KR102228571B1/ko
Publication of KR102228571B9 publication Critical patent/KR102228571B9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020170018235A 2017-02-09 2017-02-09 정신질환 또는 중추신경계 질환 치료용 약물전달 제형 KR102228571B1 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020170018235A KR102228571B1 (ko) 2017-02-09 2017-02-09 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
JP2019543230A JP6893369B2 (ja) 2017-02-09 2018-02-08 精神疾患または中枢神経系疾患治療用薬物伝達剤形
EP18751180.3A EP3581175B1 (en) 2017-02-09 2018-02-08 Drug drug delivery formulation for treating mental illness or central nervous system disorder
PCT/KR2018/001719 WO2018147660A1 (ko) 2017-02-09 2018-02-08 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
US16/484,870 US11337929B2 (en) 2017-02-09 2018-02-08 Drug delivery formulation for treating mental illness or central nervous system disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170018235A KR102228571B1 (ko) 2017-02-09 2017-02-09 정신질환 또는 중추신경계 질환 치료용 약물전달 제형

Publications (3)

Publication Number Publication Date
KR20180092497A KR20180092497A (ko) 2018-08-20
KR102228571B1 KR102228571B1 (ko) 2021-03-16
KR102228571B9 true KR102228571B9 (ko) 2023-02-23

Family

ID=63106888

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170018235A KR102228571B1 (ko) 2017-02-09 2017-02-09 정신질환 또는 중추신경계 질환 치료용 약물전달 제형

Country Status (5)

Country Link
US (1) US11337929B2 (ko)
EP (1) EP3581175B1 (ko)
JP (1) JP6893369B2 (ko)
KR (1) KR102228571B1 (ko)
WO (1) WO2018147660A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017139487A1 (en) 2016-02-09 2017-08-17 Northwind Medical, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
CN112638437B (zh) 2018-07-02 2023-12-08 图拉维治疗股份有限公司 原位形成神经帽的方法和装置
KR102272756B1 (ko) 2018-09-11 2021-07-05 주식회사 메디폴리머 정신질환 또는 중추신경계 질환 치료용 서방형 약물전달 제형 및 이의 제조방법
KR102599100B1 (ko) * 2020-10-29 2023-11-06 강원대학교산학협력단 히알루론산 분해효소 저해제가 도입된 가교결합된 히알루론산 하이드로겔
CN117120033A (zh) * 2021-03-30 2023-11-24 图拉维治疗股份有限公司 用于神经消融的方法和组合物
KR102652905B1 (ko) * 2021-08-09 2024-04-01 주식회사 메디폴리머 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767897B2 (en) * 1994-05-04 2004-07-27 Innapharma, Inc. Therapeutic uses of tri-, tetra-, penta-, and polypeptides
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
JP4636883B2 (ja) * 2002-11-21 2011-02-23 中外製薬株式会社 薬物徐放担体
EP1576952A1 (en) * 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
JP2008517927A (ja) 2004-10-21 2008-05-29 ユニバーシティー オブ アイオワ リサーチ ファンデーション ｉｎｓｉｔｕ制御放出薬剤送達システム
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
KR20100083118A (ko) 2010-07-02 2010-07-21 한양대학교 산학협력단 약물 담지 미립구의 제조방법 및 장치와 이를 이용하여 제조된 전립선 비대증 치료용 제제
GB201101429D0 (en) 2011-01-27 2011-03-16 Biocompatibles Uk Ltd Drug delivery system
CN103764172A (zh) 2011-06-27 2014-04-30 科里斯塔鲁传送有限公司 控释系统
WO2014205126A1 (en) * 2013-06-19 2014-12-24 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
EP3191016B1 (en) * 2014-09-09 2021-10-27 University of Washington Functionalized zwitterionic and mixed charge polymers, related hydrogels, and methods for their use
KR20160046570A (ko) * 2014-10-21 2016-04-29 아주대학교산학협력단 염증성 또는 통증성 질환 치료를 위한 복합 약물 전달 제형 및 이것의 제조방법
US10548989B2 (en) 2015-04-07 2020-02-04 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
EP3325029B1 (en) 2015-07-22 2023-05-24 Temple University Of The Commonwealth System Of Higher Education Soy-derived bioactive peptides for use in compositions and methods for wound healing, tissue engineering, and regenerative medicine

Also Published As

Publication number Publication date
EP3581175A4 (en) 2020-12-23
KR102228571B1 (ko) 2021-03-16
JP2020507574A (ja) 2020-03-12
US11337929B2 (en) 2022-05-24
JP6893369B2 (ja) 2021-06-23
KR20180092497A (ko) 2018-08-20
EP3581175B1 (en) 2023-12-13
US20190374476A1 (en) 2019-12-12
EP3581175A1 (en) 2019-12-18
WO2018147660A1 (ko) 2018-08-16

Similar Documents

Publication Publication Date Title
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
EP3429605A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM
KR102228571B9 (ko) 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
EP3389725A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
HK1215119A1 (zh) 治療產品遞送系統和配對方法
IL267622A (en) Method for modifying the therapeutic effects of drugs
HK1252771A1 (zh) 用於治療眼部病狀的玻璃體內藥物遞送系統
ZA201903003B (en) Treatment of neurological diseases
HK1243657A1 (zh) 用於靶向輸送治療性植入物的裝置
EP3413898A4 (en) USE OF TREHALOSIS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
GB201412578D0 (en) Treatment of neurological diseases
ZA202004433B (en) Therapeutic agent for nervous system disease
EP3544670A4 (en) PLACEMENT SYSTEM FOR INTRACORPOREAL SMOOTH MUSCLE STIMULATION
GB201714307D0 (en) Treatment of neurodegenerative diseases
KR102272756B9 (ko) 정신질환 또는 중추신경계 질환 치료용 서방형 약물전달 제형 및 이의 제조방법
IL284411A (en) Targeted transport of drug molecules
EP3471775A4 (en) HEMOGLOBIN-TARGETED DRUG ADMINISTRATION FOR CANCER TREATMENT
GB2558494B (en) Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB201714303D0 (en) Treatment of neurodegenerative diseases
NO20161568A1 (en) A new drug delivery system for treatment of cancer
GB201706662D0 (en) Treatment of neurological diseases
GB201704666D0 (en) Treatment of neurodegenerative diseases
GB201715763D0 (en) Treatment of neurological disease
GB201604253D0 (en) Treatment of genetic diseases

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]